Analytical Data
-
Gene name
CYP2W1
- Application
-
Alternative Names
CP2W1_HUMAN; CYP2W 1; CYP2W1; CYPIIW1; Cytochrome P450 2W1; Cytochrome P450; family 2; subfamily W; polypeptide 1; MGC34287
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TAV3
-
Expression Region
1-434aa
-
AA Sequence
MELSERYGPAFTVHLGRQKTVVLTGFEAVKEALAGPGQELADRPPIAIFQLIQRGGGIFFSSGARWRAARQFTVRALHSLGVGREPVADKILQELKCLSGQLDGYRGRPFPLALLGWAPSNITFALLFGRRFDYRDPVFVSLLSLIDEVMVLLGSPGLQLFNVYPWLGALLQLHRPVLRKIEEVRAILRTLLEARRPHVCPGDPVCSYVDALIQQGQGDDPEGLFAEANAVACTLDMVMAGTETTSATLQWAALLMGRHPDVQGRVQEELDRVLGPGRTPRLEDQQALPYTSAVLHEVQRFITLLPHVPRCTAADTQLGGFLLPKGTPVIPLLTSVLLDETQWQTPGQFNPGHFLDANGHFVKREAFLPFSAGRRVCVGERLARTELFLLFAGLLQRYRLLPPPGVSPASLDTTPARAFTMRPRAQALCAVPRP
-
Molecular Weight
73.48 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2W1, a member of the cytochrome P450 superfamily, has garnered significant interest in recent years due to its unique expression profile and potential role in drug metabolism and cancer biology. While traditional CYP enzymes primarily function in drug metabolism, CYP2W1 shows a distinctive pattern of expression, being predominantly found in various cancer tissues such as colorectal and lung tumors, with limited expression in normal tissues. This differential expression raises questions about its role in tumorigenesis and the potential for it to serve as a biomarker for cancer diagnosis. Furthermore, studies have suggested that CYP2W1 may be involved in the bioactivation of procarcinogens, which positions it as a candidate for understanding cancer progression and the metabolism of xenobiotics. Recent advances in recombinant protein technology have allowed for the expression and characterization of CYP2W1, providing insights into its enzymatic activity and substrate specificity. These studies are critical for elucidating the biological functions of CYP2W1 and exploring its implications in pharmacogenomics and personalized medicine. Understanding the mechanisms underlying CYP2W1's involvement in cancer could pave the way for innovative therapeutic strategies targeting this enzyme, contributing to the development of more effective cancer treatments. As research continues, CYP2W1 could emerge as a significant player in both drug metabolism and oncology, making it a promising focus for future investigations in the field of biochemical research.
